FUNDC2 Promotes Liver Tumorigenesis by Inhibiting MFN1-mediated Mitochondrial Fusion

Shuaifeng Li,Shixun Han,Qi Zhang,Yibing Zhu,Haitao Zhang,Junli Wang,Yang Zhao,Jianhui Zhao,Lin Su,Li,Dawang Zhou,Cunqi Ye,Xin-Hua Feng,Tingbo Liang,Bin Zhao
DOI: https://doi.org/10.1038/s41467-022-31187-6
IF: 16.6
2022-01-01
Nature Communications
Abstract:Mitochondria generate ATP and play regulatory roles in various cellular activities. Cancer cells often exhibit fragmented mitochondria. However, the underlying mechanism remains elusive. Here we report that a mitochondrial protein FUN14 domain containing 2 (FUNDC2) is transcriptionally upregulated in primary mouse liver tumors, and in approximately 40% of human hepatocellular carcinoma (HCC). Importantly, elevated FUNDC2 expression inversely correlates with patient survival, and its knockdown inhibits liver tumorigenesis in mice. Mechanistically, the amino-terminal region of FUNDC2 interacts with the GTPase domain of mitofusin 1 (MFN1), thus inhibits its activity in promoting fusion of outer mitochondrial membrane. As a result, loss of FUNDC2 leads to mitochondrial elongation, decreased mitochondrial respiration, and reprogrammed cellular metabolism. These results identified a mechanism of mitochondrial fragmentation in cancer through MFN1 inhibition by FUNDC2, and suggested FUNDC2 as a potential therapeutic target of HCC.
What problem does this paper attempt to address?